Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 03, 2015 1:39 AM ET

Pharmaceuticals

Company Overview of Hydra Biosciences, Inc.

Company Overview

Hydra Biosciences, Inc., a biopharmaceutical company, engages in the identification and development of therapeutic agents that treat pain, inflammation, anxiety, renal, and pulmonary diseases. The company was founded in 2001 and is based in Cambridge, Massachusetts.

45 Moulton Street

Cambridge, MA 02138

United States

Founded in 2001

Phone:

617-494-5230

Fax:

617-494-5245

Key Executives for Hydra Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 56
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Avisory Board - Cardiac Regeneration
Scientific Co-Founder, Chair of Scientific Advisory Board and Member of Pain Medical Advisory Board
Interim Chief Financial Officer
Compensation as of Fiscal Year 2015.

Hydra Biosciences, Inc. Key Developments

Hydra Biosciences Announces Executive Appointments to Newly Created Pain Medical Advisory Board

Hydra Biosciences announced newly formed pain medical advisory board (MAB) with the appointments of three leading physicians and scientists, Dr. Robert Dworkin, Dr. Roy Freeman and Dr. Nathaniel Katz. Dr. Paul Goldenheim, member of the Hydra Biosciences Board of Directors and Hydra founder, Dr. David Clapham, chair of the Hydra Scientific Advisory Board, also have seats on the MAB, which will provide clinical and scientific guidance as Hydra continues to develop HX-100, its clinical stage TRPA1 antagonist, in painful diabetic neuropathy. Robert Dworkin, Ph.D., is a professor of anesthesiology, neurology, oncology and psychiatry in the Center for Human Experimental Therapeutics, and director of the Anesthesiology Clinical Research Center at the University of Rochester School of Medicine and Dentistry. Roy Freeman, M.D., is a professor of neurology at Harvard Medical School and director of the Center for Autonomic and Peripheral Nerve Disorders in the Department of Neurology at Beth Israel Deaconess Medical Center in Boston. Dr. Freeman also is chairman of the World Federation of Neurology research group on the autonomic nervous system. Nathaniel Katz, M.D.is a neurologist and pain management specialist with a distinguished career spanning Harvard Medical School, Brigham and Women’s Hospital and Dana-Farber Cancer Institute. Dr. Katz also served as Chair of the Advisory Committee, Anesthesia, Critical Care and Addiction Products Division for the FDA.

Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM

Hydra Biosciences, Inc. Presents at Boston CEO Conference, May-27-2015 02:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Russell H. Herndon, Chief Executive Officer, President and Director.

Hydra Biosciences Receives Approval from Health Canada to Begin Phase 1 Trial for HX-100

Hydra Biosciences announced that Health Canada approved the company’s Clinical Trial Application (CTA) to begin a Phase 1 study of HX-100. This study will provide the safety data necessary for Phase 2 studies in painful diabetic neuropathy (PDN) and allergic asthma that are expected to begin later this year. TRP channels are membrane-bound proteins that play a role in controlling cellular calcium levels and excitability in response to a variety of stimuli. The 28 members of the TRP family differ from better-known ion channels in that they are not primarily voltage gated and have significant sequence diversity, providing the opportunity to develop truly selective modulators. In addition to their well-documented role in pain and pulmonary disorders, TRPs have been linked to CNS, renal and dermatological diseases. TRPA1 is a member of the TRP family, activated by reactive chemicals, products of aberrant glucose metabolism, tissue injury, and inflammation. Environmental irritants that lead to channel activity include common asthma triggers such as cigarette smoke, ozone and chlorine. HX-100 is a highly selective, potent inhibitor of TRPA1. Pre-clinical data demonstrate promising safety and efficacy with several potential advantages over currently available treatments for chronic pain and asthma. HX-100 can be taken orally, and it is expected to have robust efficacy without abuse liabilities, given the limited expression of TRPA1 in the brain. This Phase 1 trial of HX-100 follows a standard single ascending dose and multiple ascending dose design with approximately 90 healthy volunteers. The company expects to initiate separate Phase 2 studies in painful diabetic neuropathy and allergic asthma in late 2015 with results from these trials expected before the end of 2016.

Similar Private Companies By Industry

Company Name Region
Antipodean Pharmaceuticals, Inc United States
Chase Pharmaceuticals Corporation, Inc. United States
Pinnacle Pharmaceuticals, Inc. United States
Derma Life Science Inc United States
Oceana Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 17, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hydra Biosciences, Inc., please visit www.hydrabiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.